Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapies to treat a variety of diseases, including cancer and autoimmune disorders. The company specializes in applying its proprietary drug delivery technology to enhance the efficacy and safety of existing therapies, as well as creating new treatments from the ground up. Nektar collaborates with other pharmaceutical organizations to advance its research pipeline and aims to address unmet medical needs by delivering transformative medicines that improve patients' lives. Read More
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment.
